Sign in or create an account to add this stock to your watchlist.
About Genesis HealthCare (NYSE:GEN)
Genesis Healthcare, Inc. is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services. As of December 31, 2016, the Company offered inpatient services through its network of 499 skilled nursing and assisted/senior living facilities across 34 states, consisting of 473 skilled nursing facilities and 26 stand-alone assisted/senior living facilities. Its services focus primarily on the medical and physical issues facing elderly patients and are provided by its skilled nursing companies, assisted or senior living communities, integrated and third-party rehabilitation therapy business, and other ancillary services.
Industry, Sector and Symbol
Industry Skilled nursing care facilities
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GEN
CUSIPN/A
Phone610-444-6350
Debt
Debt-to-Equity Ratio-2.80
Current Ratio1.11
Quick Ratio1.11
Price-To-Earnings
Trailing P/E Ratio-0.97
Forward P/E Ratio-1.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.37 billion
Price / Sales0.06
Cash Flow$2.4938 per share
Price / Cash0.81
Book Value($11.21) per share
Price / Book-0.18
Profitability
EPS (Most Recent Fiscal Year)($2.11)
Net Income$-578,980,000.00
Net Margins-11.29%
Return on EquityN/A
Return on Assets-2.73%
Miscellaneous
Employees68,700
Outstanding Shares159,450,000
Genesis HealthCare (NYSE:GEN) Frequently Asked Questions
What is Genesis HealthCare's stock symbol?
Genesis HealthCare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN."
How were Genesis HealthCare's earnings last quarter?
Genesis HealthCare (NYSE:GEN) issued its earnings results on Thursday, May, 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.34. The firm had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the previous year, the business earned ($0.55) earnings per share. View Genesis HealthCare's Earnings History.
What price target have analysts set for GEN?
4 brokerages have issued 1-year price targets for Genesis HealthCare's stock. Their predictions range from $2.00 to $2.00. On average, they expect Genesis HealthCare's share price to reach $2.00 in the next twelve months. View Analyst Ratings for Genesis HealthCare.
Who are some of Genesis HealthCare's key competitors?
Some companies that are related to Genesis HealthCare include Impax Laboratories (IPXL), Audentes Therapeutics (BOLD), Radius Health (RDUS), Amneal Pharmaceuticals (AMRX), Biohaven Pharmaceutical (BHVN), Drägerwerk (DRW3), Myovant Sciences (MYOV), TherapeuticsMD (TXMD), Cellectis (CLLS), Theravance Biopharma (TBPH), Epizyme (EPZM), WAVE Life Sciences (WVE), Adaptimmune Therapeutics (ADAP), Luminex (LMNX) and Glaukos (GKOS).
Who are Genesis HealthCare's key executives?
Genesis HealthCare's management team includes the folowing people:
- Robert H. Fish, Chairman of the Board
- George V. Hager Jr., Chief Executive Officer, Director
- Thomas DiVittorio, Chief Financial Officer
- Paul David Bach, Chief Operating Officer
- Jeanne Phillips, Chief Human Resource Officer, Senior Vice President
- , Bio & Compensation -
- David C. Almquist, Executive Vice President, President - West and East Divisions
- Richard P. Blinn, Executive Vice President, President - Northeast Division and Southeast Divisions
- JoAnne Reifsnyder Ph.D., Executive Vice President - Clinical Operations, Chief Nursing Officer
- Richard L. Castor, Senior Vice President, Chief Information Officer
- Michael S. Sherman, Senior Vice President, General Counsel, Assistant Treasurer, Secretary
Has Genesis HealthCare been receiving favorable news coverage?
News stories about GEN stock have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genesis HealthCare earned a news impact score of 0.21 on Accern's scale. They also assigned media headlines about the company an impact score of 46.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Genesis HealthCare's major shareholders?
Genesis HealthCare's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Columbia Pacific Advisors LLC (3.86%), First Washington CORP (1.88%), V3 Capital Management L.P. (1.60%), BlackRock Inc. (1.44%), Glassman Wealth Services (0.70%) and Prescott Group Capital Management L.L.C. (0.37%). Company insiders that own Genesis HealthCare stock include Daniel Allen Hirschfeld, George V Hager Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Institutional Ownership Trends for Genesis HealthCare.
Which major investors are selling Genesis HealthCare stock?
GEN stock was sold by a variety of institutional investors in the last quarter, including Prescott Group Capital Management L.L.C., Columbia Pacific Advisors LLC, JPMorgan Chase & Co., First Washington CORP, Forward Management LLC and Northern Trust Corp. Company insiders that have sold Genesis HealthCare company stock in the last year include Daniel Allen Hirschfeld, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View Insider Buying and Selling for Genesis HealthCare.
Which major investors are buying Genesis HealthCare stock?
GEN stock was acquired by a variety of institutional investors in the last quarter, including Glassman Wealth Services, V3 Capital Management L.P., BlackRock Inc., Schwab Charles Investment Management Inc., Millennium Management LLC, California Public Employees Retirement System and BSW Wealth Partners. View Insider Buying and Selling for Genesis HealthCare.
How do I buy shares of Genesis HealthCare?
Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genesis HealthCare's stock price today?
One share of GEN stock can currently be purchased for approximately $2.02.
How big of a company is Genesis HealthCare?
Genesis HealthCare has a market capitalization of $338.02 million and generates $5.37 billion in revenue each year. The company earns $-578,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Genesis HealthCare employs 68,700 workers across the globe.
How can I contact Genesis HealthCare?
Genesis HealthCare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected]
MarketBeat Community Rating for Genesis HealthCare (GEN)
MarketBeat's community ratings are surveys of what our community members think about Genesis HealthCare and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Genesis HealthCare (NYSE:GEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Genesis HealthCare in the last 12 months. Their average twelve-month price target is $2.00, suggesting that the stock has a possible downside of 0.99%. The high price target for GEN is $2.00 and the low price target for GEN is $2.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.25 | 2.25 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.00 | $2.00 | $2.00 | $2.00 |
| Price Target Upside: | 0.99% downside | 42.86% upside | 96.08% upside | 96.08% upside |
Genesis HealthCare (NYSE:GEN) Consensus Price Target History
Genesis HealthCare (NYSE:GEN) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Genesis HealthCare (NYSE:GEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Genesis HealthCare (NYSE GEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 58.10%
Institutional Ownership Percentage: 18.70%
Genesis HealthCare (NYSE GEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/14/2017 | Joanne Susan Reifsnyder | EVP | Sell | 5,269 | $1.73 | $9,115.37 | |  |
| 6/14/2017 | Michael Scott Sherman | SVP | Sell | 3,903 | $1.73 | $6,752.19 | | |
| 6/14/2017 | Paul David Bach | COO | Sell | 6,100 | $1.73 | $10,553.00 | | |
| 6/14/2017 | Stephen Scott Young | VP | Sell | 3,799 | $1.73 | $6,572.27 | | |
| 6/14/2017 | Thomas Divittorio | CFO | Sell | 6,341 | $1.73 | $10,969.93 | | |
| 6/7/2017 | Daniel Allen Hirschfeld | COO | Sell | 2,895 | $1.61 | $4,660.95 | | |
| 6/7/2017 | Joanne Susan Reifsnyder | EVP | Sell | 2,383 | $1.61 | $3,836.63 | | |
| 6/7/2017 | Michael Scott Sherman | SVP | Sell | 1,824 | $1.61 | $2,936.64 | | |
| 6/7/2017 | Stephen Scott Young | VP | Sell | 1,541 | $1.61 | $2,481.01 | | |
| 6/7/2017 | Thomas Divittorio | CFO | Sell | 2,900 | $1.61 | $4,669.00 | | |
| 8/29/2016 | Stephen Scott Young | VP | Sell | 10,000 | $2.38 | $23,800.00 | | |
| 6/8/2016 | Daniel Allen Hirschfeld | COO | Sell | 3,009 | $1.72 | $5,175.48 | 488,220 | |
| 6/8/2016 | George V Hager Jr | CEO | Sell | 6,031 | $1.72 | $10,373.32 | 1,542,780 | |
| 6/8/2016 | Joanne Susan Reifsnyder | EVP | Sell | 2,207 | $1.72 | $3,796.04 | 286,468 | |
| 6/8/2016 | Michael Scott Sherman | SVP | Sell | 1,919 | $1.72 | $3,300.68 | 423,220 | |
| 6/8/2016 | Stephen Scott Young | VP | Sell | 1,621 | $1.72 | $2,788.12 | 172,495 | |
| 6/8/2016 | Thomas Divittorio | CFO | Sell | 3,051 | $1.72 | $5,247.72 | 509,220 | |
| 11/12/2015 | James V Mckeon | Director | Buy | 10,000 | $4.15 | $41,500.00 | 29,802 | |
| 11/11/2015 | Thomas Divittorio | CFO | Buy | 20,000 | $4.34 | $86,800.00 | 387,220 | |
| 11/14/2013 | Boyd Hendrickson | CEO | Sell | 48,774 | $5.02 | $244,845.48 | 265,430 | |
| 8/6/2013 | Boyd W Hendrickson | CEO | Sell | 4,983 | $6.03 | $30,047.49 | | |
| 8/5/2013 | Boyd W Hendrickson | CEO | Sell | 24,671 | $6.49 | $160,114.79 | | |
| 8/2/2013 | Boyd W Hendrickson | CEO | Sell | 45,346 | $6.58 | $298,376.68 | | |
| 7/2/2013 | Boyd W Hendrickson | CEO | Sell | 29,988 | $6.46 | $193,722.48 | | |
| 7/1/2013 | Boyd W Hendrickson | CEO | Sell | 28,112 | $6.61 | $185,820.32 | | |
| 11/1/2012 | Boyd W Hendrickson | CEO | Sell | 1,567 | $8.00 | $12,536.00 | | |
(Data available from 1/1/2013 forward)
Genesis HealthCare (NYSE GEN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma
finance.yahoo.com - May 24 at 5:27 PM |
 | Quorum Health Corporation Announces Leadership Transition
www.bizjournals.com - May 21 at 8:28 AM |
| FOCUS-A bid to save $300 million at HCR ManorCare, and disrupt U.S. healthcare
finance.yahoo.com - May 15 at 8:46 AM |
| Free Stock Performance Review on Envision Healthcare and Three More Long-Term Care Facilities Stocks
finance.yahoo.com - May 14 at 8:46 AM |
 | Genesis HealthCare (GEN) Announces Quarterly Earnings Results, Misses Estimates By $0.34 EPS
www.americanbankingnews.com - May 12 at 1:35 PM |
 | Genesis Healthcare's (GEN) CEO George Hager on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 5:40 PM |
| Edited Transcript of GEN earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 8:48 AM |
| Genesis Healthcare EPS of -$0.70
seekingalpha.com - May 10 at 8:37 AM |
 | BRIEF-Genesis Healthcare Says Qtrly Loss Per Share Attributable To Co $0.70
www.reuters.com - May 10 at 8:37 AM |
| Genesis HealthCare Reports First Quarter 2018 Results
finance.yahoo.com - May 10 at 8:37 AM |
| Genesis Healthcare: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:37 AM |
| Interim Report First Quarter 2018
finance.yahoo.com - May 8 at 5:25 PM |
| Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma
finance.yahoo.com - May 8 at 8:30 AM |
| Genesis Healthcare Expects to Release First Quarter 2018 Results on May 10, 2018
finance.yahoo.com - May 8 at 8:30 AM |
| Genesis HealthCare (GEN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 2 at 8:10 PM |
 | Form DEF 14A Genesis Healthcare, Inc. For: Jun 06
www.streetinsider.com - April 29 at 8:39 AM |
| Form DEFA14A Genesis Healthcare, Inc.
www.streetinsider.com - April 29 at 8:39 AM |
| What You Must Know About Genomed Spólka Akcyjna’s (WSE:GEN) Major Investors
finance.yahoo.com - April 26 at 8:28 AM |
| Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting
finance.yahoo.com - April 25 at 5:20 PM |
 | Citigroup Inc., Genesis Healthcare, Molson Coors Brewing Co., Tempur Sealy International, Overstock.com, and 75 Other Companies Join NACD in Q1 2018
globenewswire.com - April 24 at 5:26 PM |
| $30M deal: Genesis to sell 51% stake in China subsidiary
finance.yahoo.com - April 24 at 5:26 PM |
| Stifel Nicolaus Reiterates "$2.00" Price Target for Genesis HealthCare (GEN)
www.americanbankingnews.com - April 24 at 4:18 PM |
| Reviewing Ensign Group (ENSG) & Genesis HealthCare (GEN)
www.americanbankingnews.com - April 24 at 3:32 PM |
| Sabra: A Healthcare REIT With Tailwinds And A 10.5% Dividend
seekingalpha.com - April 23 at 5:04 PM |
| Genesis HealthCare Sells 51% Stake in Chinese Subsidiary GRS-HS to Riswein Health Industry Investment Co., Ltd
finance.yahoo.com - April 23 at 5:04 PM |
| -$0.31 EPS Expected for Genesis HealthCare (GEN) This Quarter
www.americanbankingnews.com - April 20 at 11:28 AM |
| Genesis HealthCare (GEN) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018
finance.yahoo.com - April 17 at 8:47 AM |
| Genesis selling off 2 dozen skilled nursing facilities in Texas
finance.yahoo.com - April 12 at 5:23 PM |
| Centers Health Care Hires Heidi Hendrix, RN, As New Chief Nursing Officer
www.bizjournals.com - April 12 at 8:59 AM |
| Genesis Healthcare to divest 23 nursing facilities
seekingalpha.com - April 12 at 8:59 AM |
| Can Genomed Spólka Akcyjna (WSE:GEN) Improve Your Portfolio Returns?
finance.yahoo.com - April 12 at 8:59 AM |
| Genesis Energy Limited (NZE:GNE): Time For A Financial Health Check
finance.yahoo.com - April 11 at 8:46 AM |
| Passing of Genmab A/S’ Annual General Meeting
finance.yahoo.com - April 10 at 5:19 PM |
| Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
finance.yahoo.com - April 10 at 5:19 PM |
| Should You Expect Genomed Spólka Akcyjna (WSE:GEN) To Continue Delivering An ROE Of 29.39%?
finance.yahoo.com - April 4 at 4:02 PM |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise
finance.yahoo.com - April 3 at 5:22 PM |
| ValuEngine Downgrades Genesis Healthcare (GEN) to Hold
www.americanbankingnews.com - April 3 at 2:58 PM |
| Quorum Health (QHC) Names Terry Allison Rappuhn as New Chair; William M. Gracey Resigns
www.streetinsider.com - March 26 at 8:36 AM |
| Quorum Health (QHC) Names Terry Allison Rappuhn as New Chair; William M. Gracey Resigns - StreetInsider.com
www.streetinsider.com - March 24 at 9:01 AM |
![Genesis Healthcare riding nursing-home turbulence [Philly.com]](/images/news-sites/bloomberg.jpg "Genesis Healthcare riding nursing-home turbulence [Philly.com]") | Genesis Healthcare riding nursing-home turbulence [Philly.com]
www.bloomberg.com - March 22 at 5:25 PM |
| Genesis Rehab Services Achieves “World Class” Net Promoter Score
finance.yahoo.com - March 22 at 5:25 PM |
| Genesis Healthcare (GEN) & Its Competitors Head-To-Head Survey
www.americanbankingnews.com - March 22 at 1:38 PM |
| Genesis Healthcare (GEN) Rating Reiterated by Stephens
www.americanbankingnews.com - March 19 at 9:30 PM |
| Should You Be Tempted To Buy Genomed Spólka Akcyjna (WSE:GEN) Because Of Its PE Ratio?
finance.yahoo.com - March 19 at 5:08 PM |
| Genesis Healthcare, Inc. (GEN) PT Raised to $2 at Stephens - StreetInsider.com
www.streetinsider.com - March 19 at 8:36 AM |
| Canon Medical Systems’ Aquilion ONE / GENESIS Edition Delivers Full Suite of Acute Stroke Solutions
www.bizjournals.com - March 18 at 8:31 AM |
| Edited Transcript of GEN earnings conference call or presentation 16-Mar-18 12:30pm GMT
finance.yahoo.com - March 17 at 8:42 AM |
| Genesis Healthcare (GEN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 16 at 6:16 PM |
| Genesis Healthcare reports 4Q loss
finance.yahoo.com - March 16 at 8:34 AM |
Genesis HealthCare (NYSE:GEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Genesis HealthCare (NYSE:GEN) Income Statement, Balance Sheet and Cash Flow Statement
Genesis HealthCare (NYSE GEN) Stock Chart for Friday, May, 25, 2018
Loading chart…
